W-Y Huang1, J-B Wen2, G Wu3, B Yin2, J-J Li4, D-Y Geng5. 1. From the Departments of Radiology (W.-Y.H., J.-J.L.). 2. Department of Radiology (J.-B.W., B.Y., D.-Y.G.), Huashan Hospital, Fudan University, Shanghai, China. 3. Radiotherapy (G.W.), Hainan General Hospital, Haikou, Hainan, China. 4. From the Departments of Radiology (W.-Y.H., J.-J.L.) lijianjunhngh@163.com gengdaoying2245@163.com. 5. Department of Radiology (J.-B.W., B.Y., D.-Y.G.), Huashan Hospital, Fudan University, Shanghai, China. lijianjunhngh@163.com gengdaoying2245@163.com.
Abstract
BACKGROUND AND PURPOSE: Whether ADC value predicts the therapy response and outcomes of primary central system lymphoma remains controversial. This study assessed the minimum ADC correlated with treatment response in patients with primary central nervous system lymphoma undergoing methotrexate-based chemotherapy. MATERIALS AND METHODS: Thirty-five patients with primary central nervous system lymphoma underwent conventional MR imaging and DWI before chemotherapy and after 1 and 5 cycles of chemotherapy. Treatment response was determined according to the International PCNSL Collaborative Group criteria and was classified as a complete response, partial response, or progressive disease. Pretreatment minimum ADC, minimum ADC after 1 cycle, minimum ADC after 5 cycles, and change in minimum ADC were compared among the different response groups. The Pearson correlation test was calculated between these ADC parameters and tumor response. RESULTS: The pretreatment minimum ADC of the progressive disease group was lower than that of the complete response and partial response groups, but there was no significant difference among them. The minimum ADC after 1 cycle and minimum ADC after 5 cycles were statistically significantly higher than the pretreatment minimum ADC. A comparison among groups showed that minimum ADC after 1 cycle, minimum ADC after 5 cycles, minimum ADC change, and the percentage of minimum ADC change were all significantly different among the 3 groups. A significant positive correlation was observed between the percentage of minimum ADC after 1 cycle of chemotherapy and the size reduction percentage after 5 cycles of chemotherapy. The minimum ADC change and the percentage of minimum ADC change performed better in the differentiation of the final treatment response, specifically in complete response and partial response from progressive disease. CONCLUSIONS: The minimum ADC after 1 cycle and minimum ADC changes were better correlated with the treatment response than the pretreatment minimum ADC. Minimum ADC after early therapy may potentially to be used to predict and monitor the response of primary central nervous system lymphoma to chemotherapy.
BACKGROUND AND PURPOSE: Whether ADC value predicts the therapy response and outcomes of primary central system lymphoma remains controversial. This study assessed the minimum ADC correlated with treatment response in patients with primary central nervous system lymphoma undergoing methotrexate-based chemotherapy. MATERIALS AND METHODS: Thirty-five patients with primary central nervous system lymphoma underwent conventional MR imaging and DWI before chemotherapy and after 1 and 5 cycles of chemotherapy. Treatment response was determined according to the International PCNSL Collaborative Group criteria and was classified as a complete response, partial response, or progressive disease. Pretreatment minimum ADC, minimum ADC after 1 cycle, minimum ADC after 5 cycles, and change in minimum ADC were compared among the different response groups. The Pearson correlation test was calculated between these ADC parameters and tumor response. RESULTS: The pretreatment minimum ADC of the progressive disease group was lower than that of the complete response and partial response groups, but there was no significant difference among them. The minimum ADC after 1 cycle and minimum ADC after 5 cycles were statistically significantly higher than the pretreatment minimum ADC. A comparison among groups showed that minimum ADC after 1 cycle, minimum ADC after 5 cycles, minimum ADC change, and the percentage of minimum ADC change were all significantly different among the 3 groups. A significant positive correlation was observed between the percentage of minimum ADC after 1 cycle of chemotherapy and the size reduction percentage after 5 cycles of chemotherapy. The minimum ADC change and the percentage of minimum ADC change performed better in the differentiation of the final treatment response, specifically in complete response and partial response from progressive disease. CONCLUSIONS: The minimum ADC after 1 cycle and minimum ADC changes were better correlated with the treatment response than the pretreatment minimum ADC. Minimum ADC after early therapy may potentially to be used to predict and monitor the response of primary central nervous system lymphoma to chemotherapy.
Authors: Lauren E Abrey; Tracy T Batchelor; Andrés J M Ferreri; Mary Gospodarowicz; Elisa J Pulczynski; Emanuele Zucca; Justine R Smith; Agnieszka Korfel; Carole Soussain; Lisa M DeAngelis; Edward A Neuwelt; Brian Patrick O'Neill; Eckhard Thiel; Tamara Shenkier; Fransesc Graus; Martin van den Bent; John F Seymour; Philip Poortmans; James O Armitage; Franco Cavalli Journal: J Clin Oncol Date: 2005-06-13 Impact factor: 44.544
Authors: Kuei C Lee; Bradford A Moffat; Anne F Schott; Rachel Layman; Steven Ellingworth; Rebecca Juliar; Amjad P Khan; Mark Helvie; Charles R Meyer; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross Journal: Clin Cancer Res Date: 2007-01-15 Impact factor: 12.531
Authors: Matthew J Wieduwilt; Francisco Valles; Samar Issa; Caroline M Behler; James Hwang; Michael McDermott; Patrick Treseler; Joan O'Brien; Marc A Shuman; Soonmee Cha; Lloyd E Damon; James L Rubenstein Journal: Clin Cancer Res Date: 2012-01-06 Impact factor: 12.531
Authors: S Nakajima; T Okada; A Yamamoto; M Kanagaki; Y Fushimi; T Okada; Y Arakawa; Y Takagi; S Miyamoto; K Togashi Journal: Clin Radiol Date: 2015-09-14 Impact factor: 2.350
Authors: A Server; B Kulle; J Maehlen; R Josefsen; T Schellhorn; T Kumar; C W Langberg; P H Nakstad Journal: Acta Radiol Date: 2009-07 Impact factor: 1.990
Authors: Roopesh Kansara; Tamara N Shenkier; Joseph M Connors; Laurie H Sehn; Kerry J Savage; Alina S Gerrie; Diego Villa Journal: Am J Hematol Date: 2015-11-17 Impact factor: 10.047
Authors: R Kurokawa; A Baba; M Kurokawa; A Capizzano; O Hassan; T Johnson; Y Ota; J Kim; A Hagiwara; T Moritani; A Srinivasan Journal: AJNR Am J Neuroradiol Date: 2022-01-20 Impact factor: 3.825
Authors: Julia P Lingl; Arthur Wunderlich; Steffen Goerke; Daniel Paech; Mark E Ladd; Patrick Liebig; Andrej Pala; Soung Yung Kim; Michael Braun; Bernd L Schmitz; Meinrad Beer; Johannes Rosskopf Journal: Diagnostics (Basel) Date: 2022-02-14
Authors: Ryan Pathak; Hossein Ragheb; Neil A Thacker; David M Morris; Houshang Amiri; Joost Kuijer; Nandita M deSouza; Arend Heerschap; Alan Jackson Journal: Sci Rep Date: 2017-10-26 Impact factor: 4.379